ArticlemedRxiv : the preprint server for health sciences2025
Predictors of Supplemental Opioid Use After Third Molar Extraction.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Objectives: Non-steroidal anti-inflammatory drugs (NSAIDs) are recommended as first-line analgesics following third molar extraction, but some patients require supplemental opioids for pain management. The objective of this study was to identify demographic and clinical factors that predicted supplemental opioid use following third molar extraction in patients treated with an evidence-based analgesic regimen. Methods: Healthy adults underwent surgical extraction of partial or full bony impacted mandibular third molar. When pain intensity was ≥4/10, participants were given ibuprofen 400 mg (N=59) or placebo (N=26) in a randomized, double-blind design. After 4h, all participants transitioned to open-label ibuprofen 400 mg + acetaminophen 500 mg, with oxycodone 5 mg available for breakthrough pain. Analgesic use was documented for the first week after extraction. Predictors of supplemental opioid use in addition to ibuprofen + acetaminophen were evaluated by logistic regression. Results: Ibuprofen + acetaminophen provided adequate analgesia in most of the 85 participants, with 17 participants (20%) using supplemental oxycodone in the first week after extraction. Female sex (OR: 6.770; 95% CI: 1.657-35.57; p=0.013) and higher body mass index (BMI) (OR: 1.253; 95% CI: 1.052-1.525; p=0.016) were associated with increased odds of supplemental opioid use, while higher difficulty index (Pederson score) slightly decreased the odds of supplemental opioid use (OR: 0.852; 95% CI: 0.724-0.993; p=0.043). Adding pre-surgery neutrophil counts improved model fit, with higher neutrophil counts associated with lower odds of supplemental opioid use (OR: 0.435; 95% CI: 0.212-0.775; p=0.011). Conclusions: Female sex, higher BMI, and pre-surgery neutrophil counts were predictors of supplemental opioid use in patients treated with an evidence-based analgesic regimen. Greater surgical difficulty of third molar extraction does not increase the likelihood of supplemental opioid use.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.